The FDA has declined to approve Avanir Pharmaceuticals Inc.'s (AVNR) investigational drug-device combination product AVP-825 for the treatment of migraine.
AVP-825 delivers sumatriptan powder intranasally utilizing a novel Breath Powered delivery technology. The approval of AVP-825 is being sought under 505(b)(2) regulatory pathway and its NDA included data from one pivotal phase III clinical trial, a phase II placebo-controlled clinical trial and two pharmacokinetic studies for the acute treatment of migraine.
In the Complete Response Letter issued today, the FDA has requested the company to conduct a new human factors validation study to assess usability of the device following improvements. However, no additional clinical trials have been sought by the regulatory agency.
Avanir plans to conduct a new human factors study, with input from the FDA, and respond to the Complete Response Letter in the first half of calendar 2015.
AVNR closed Wednesday's trading at $15.01. In after-hours, the stock slipped 4.53% to $14.33.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.